Description
COMPOSITION: Each capsule contains Lenvatinib 4 mg.
INDICATION:
- LENVAKAST is indicated for The treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory diflerentiated thyroid cancer (DTc).
- LENVAKAST is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.
- LENVAKAST is also indicated for Endometrial carcinom.
PACKING: 3×10 capsules / Strip